Featured Research

from universities, journals, and other organizations

Antiviral Therapy Helps Children At Risk For Post-transplant Lymphoproliferative Disease

Date:
August 4, 2008
Source:
Wiley-Blackwell
Summary:
The antiviral drug, valganciclovir, can lower the levels of Epstein-Barr virus in children with liver transplants, according to a new study.

The antiviral drug, valganciclovir, can lower the levels of Epstein-Barr virus in children with liver transplants, according to a new study. About half of young transplant recipients with detectable levels of the virus in their blood responded to a long course of the therapy, with 60 percent maintaining their response when they stopped taking the drug.

Many pediatric liver recipients become infected with Epstein-Barr virus post-transplant, probably because the latent virus is in lymphocytes in the graft or in blood derivatives. Immunosuppressants taken to control rejection change the children's normal immune response to the virus, leading in some cases to uncontrolled lymphocyte B proliferation. Antiviral therapy is one possible way to address the danger of Epstein-Barr infection in transplant recipients.

Researchers, led by Paloma Jara of Madrid, studied the effects of valganciclovir in 47 pediatric transplant recipients with detectable Epsten-Barr DNA in their blood. They hoped to decrease the risk of post-transplant lymphoproliferative disease (PTLD) by blocking the viral replication that can lead to lymphocyte B proliferation.

After a median 8 months of treatment, EBV-DNA became undetectable in about half of the children who were asymptomatic at the start of the therapy, and no new cases of PTLD developed. In one child, who started the study with suspected PTLD, symptoms worsened over the course of the study. The safety profile was excellent, with no severe adverse events attributed to the drug.

The authors suggest that their results be interpreted with caution as they did not include a control group, and because the short timeframe for follow-up yielded no definitive conclusions about EBV outcomes.

Still, they concluded, "Valganciclovir has been shown safe in the current study and the population of children treated did not develop PTLD, warranting future trials to confirm a positive effect in the management of EBV infection."

In an accompanying editorial, Michael Green and George Mazariegos of the University of Pittsburgh, discuss their experience lowering immune suppression for patients with persistently high EBV loads, instead of using antiviral therapy.

"We have developed a relatively standardized approach to the presence of the high load carrier state which aims to gradually reduce immune suppression while carefully monitoring for any evidence of breakthrough rejection," they report.

"We agree that additional trials of valganciclovir are needed to establish a beneficial effect of this drug," they conclude.

These findings are in the August issue of Liver Transplantation, a journal by John Wiley & Sons.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Antiviral Therapy Helps Children At Risk For Post-transplant Lymphoproliferative Disease." ScienceDaily. ScienceDaily, 4 August 2008. <www.sciencedaily.com/releases/2008/07/080731140133.htm>.
Wiley-Blackwell. (2008, August 4). Antiviral Therapy Helps Children At Risk For Post-transplant Lymphoproliferative Disease. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2008/07/080731140133.htm
Wiley-Blackwell. "Antiviral Therapy Helps Children At Risk For Post-transplant Lymphoproliferative Disease." ScienceDaily. www.sciencedaily.com/releases/2008/07/080731140133.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins